Cardiff Oncology to Unveil Interim Phase 2 CRDF-004 Onvansertib Data in RAS-mCRC
Cardiff Oncology will present updated interim data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib plus FOLFIRI/bevacizumab or FOLFOX/bevacizumab in first-line RAS-mutated metastatic colorectal cancer. The rapid oral presentation is scheduled for June 2, 2026 at 8:00 AM CDT in Chicago during ASCO’s gastrointestinal cancer session.
1. Presentation Announcement
Cardiff Oncology has confirmed it will present updated interim results from its CRDF-004 randomized Phase 2 trial of onvansertib in combination with standard chemotherapy and bevacizumab at the 2026 ASCO Annual Meeting. This marks the first rapid oral session dedicated to its lead asset in first-line RAS-mutated metastatic colorectal cancer.
2. CRDF-004 Trial Design
The CRDF-004 study is a dose-finding Phase 2 trial evaluating onvansertib alongside either FOLFIRI/bevacizumab or FOLFOX/bevacizumab in patients with newly diagnosed RAS-mutated mCRC. Primary objectives include assessing safety, tolerability and preliminary efficacy signals such as objective response rates and progression-free survival.
3. ASCO Rapid Oral Session Details
The rapid oral session is set for June 2, 2026 from 8:00 to 9:30 AM CDT under the Gastrointestinal Cancer—Colorectal and Anal category. Abstract No. 3510 will be publicly available on May 21, and presentation slides will be posted on the company’s scientific publications page following the meeting.
4. Onvansertib Development Pipeline
Onvansertib is an oral PLK1 inhibitor in mid-stage development for RAS-mutated mCRC and is also under evaluation in investigator-initiated studies for metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer and chronic myelomonocytic leukemia.